SAR 404460

Drug Profile

SAR 404460

Alternative Names: SAR404460

Latest Information Update: 05 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sanofi
  • Class Glucagon-like peptides; Hormones; Omega 3 fatty acids; Vitamins
  • Mechanism of Action Insulinotropin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Muscular atrophy

Most Recent Events

  • 31 Aug 2013 Phase-I development is ongoing in France
  • 30 Jun 2012 Phase-I clinical trials in Muscular atrophy in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top